Keywords: fatty acid binding protein-3(FABP3), fatty acid binding protein-4(FABP4),
INTRODUCTION
Lung cancer is one of the primary causes of cancerrelated death worldwide and greater than 80 percent of lung cancer patients have non-small cell lung cancer (NSCLC) [1] [2] [3] . Despite improvements in treatment modalities (such as surgical resection, chemotherapy, radiotherapy, and targeted therapy), the long-term survival of NSCLC is still dismal with 5-year survival rate less than 15 percent due to cancer relapse and metastasis [4] [5] [6] . Thus, identification of novel prognostic biomarkers and therapeutic targets is urgent.
FABP3 and FABP4 belong to fatty acid binding protein (FABP) family, which control the metabolism and transportation of long-chain fatty acids. FABP3 plays various roles in fatty acid transport, cell signaling, cell growth, and gene transcription [7] . Recent clinical studies have indicated the participation of FABP3 in tumor progression with conflicting functions. In breast cancer, FABP3 acts as a tumor suppressor gene: its expression was downregulated in breast cancer samples; FABP3 cDNA transfection in breast cancer cell lines leads to a modest anti-proliferative activity [8] ; similarly, over-expression of FABP3 in embryonic cancer cells inhibits cell growth and leads apoptosis [9] . On the other hand, elevated FABP3 expression is associated with tumor progression, aggressiveness and poor prognosis in gastric carcinoma [10] . Thus far, there has been no study of FABP3 in NSCLC development and progression.
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FABP4 has been linked to the development of metabolic syndrome, diabetes, and arteriosclerosis [11] . FABP4 is a prognostic predictor in infiltrating or invasive bladder cancer [12] , and FABP4 is a potential therapeutic target for metastatic prostate cancers [13] . However, FABP4 in NSCLC has not been investigated.
Little is known about the expression of FABP3 and FABP4 in NSCLC. Here, we investigated the expression of these two markers and assessed their correlation with the clinicopathological features as well as prognosis in NSCLC. Finally, we also investigated the prognostic value of concurrent expression of FABP3 and FABP4 in NSCLC.
RESULTS

FABP3 and FABP4 mRNA expression was upregulated in NSCLC cancerous tissues
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to determine the relative expression of FABP3 and FABP4 mRNA in NSCLC cancerous (n=30) and matched adjacent non-cancerous tissues (n=30) by normalizing to the housekeeping gene GAPDH. FABP3 mRNA expression level was significantly higher in NSCLC cancerous tissues (0.64±0.12) than in matched non-cancerous tissues (0.27±0.06) (P<0.001). Similarly, FABP4 mRNA expression level was significantly higher in NSCLC cancerous tissues (0.97±0.18) than in matched non-cancerous tissues (0.50±0.09) (P<0.001) (Figure 1 ). (Figure 2 ). In NSCLC cancerous tissues, FABP3 protein expression was mainly localized in the cytoplasm, and rarely detected in the nucleus. On the contrary, the majority of FABP3 protein expression was detected in the nucleus in adjacent non-cancerous tissues. Similar protein expression pattern was observed for FABP4.
FABP3 and FABP4 protein expression was significantly higher in NSCLC cancerous tissues
Relationships of FABP3 and FABP4 protein expression with clinicopathological characteristics of NSCLC patients
In order to elucidate the function of FABP3 and FABP4 protein expression during NSCLC progression, 
DISCUSSION
In the present study, we found that both mRNA and protein expression of FABP3 and FABP4 were significantly higher in NSCLC cancerous tissues than in [14] . Recent studies have indicated that fatty acid metabolism is involved in tumorigenesis and tumor progression of many types of cancer [15] [16] [17] , by influencing tumor proliferation and tumor migration. FABPs are differentially expressed in various cancers and are suggested potential tumor biomarkers [10, [18] [19] [20] [21] [22] .
Besides its functions in lipid transport, storage, and metabolism [23] , FABP3 is also involved in cell growth and proliferation. FABP3 expression is elevated after myocardial injury, and is widely used as a marker of acute myocardial infarction and stroke [24] [25] [26] . More recent studies demonstrated the interaction between FABP3 and cancer biology in various types of cancer, including breast cancer [8] , gastric carcinoma [10] , brain tumor [27] , and small cell lung cancer [28] . Besides binding to long-chain fatty acids, FABP4 is also capable of binding to a variety of hydrophobic compounds, including cycloxygenases and oxidative products of fatty acids. It functions in both glucose and lipid metabolism [29, 30] , and is involved in signal transduction [31] , as well as in cell proliferation and apoptotic processes [32] . Its involvement in tumorigenesis has been investigated in bladder cancer [12] , breast cancer [33, 34] , ovarian cancer [35, 36] , and oral squamous cell cancer [37] . However, there have been few studies of FABPs in NSCLC patients. Our results suggest that FABP3 and FABP4 could be promising biomarkers in NSCLC. Several studies have demonstrated the association between FABP4 expression and poor prognosis in several tumors [38] [39] [40] , which were consistent with our current findings. However, the role of FABP3 in tumor is controversial: FABP3 can act as either a tumor suppressor or an oncogene depending on tumor types. In breast cancer and embryonic cancer cells, FABP3 acts as a tumor suppressor [41] : FABP3 inactivation inhibits apoptosis and promotes proliferation; while FABP3 acts as an oncogene in gastric carcinoma, brain tumor and small cell lung cancer [42] . Our study indicated that FABP3 acts as an oncogene in NSCLC.
The underlying molecular mechanism of FABP3 and FABP4 in tumorigenesis has been investigated in a few studies. Song GX et al reported that in embryonic cancer cell, FABP3 promoted apoptosis through inducing mitochondrial impairment [7] . Hu J et al described that in ovarian cancer, FABP4 promoted fatty acids absorption from adipocytes for rapid tumor growth in adipocyte-rich microenvironment [43] . Further in vitro functional studies are needed to elucidate the molecular mechanisms of FABP3 and FABP4 in NSCLC. Our finding of the positive correlation between FABP3 and FABP4 expression suggest that these two proteins may act in the same signaling pathway in promoting tumor progression. Our study confirms that fatty acid metabolism pathway is involved in tumorigenesis again. It is well documented that tumor cells have unique metabolic requirement comparing to normal cells [44] . Earlier studies have focused on glucose and glutamine metabolism pathways during tumor development. Latest research has suggested that fatty acid metabolism also plays an important role in various aspects of tumor cell proliferation, transformation and migration [45] . Mechanistically, the high proliferation rate of tumor cells requires a large amount of fatty acids [46] , not only as energy source, but also as building blocks for large biomolecules [47, 48] ; many lipid molecules can act as signaling molecules that induce carcinogenesis [49] . FABPs, a super-family of lipid binding protein, have important functions on the uptake, transport and oxidation of fatty acid and their derivatives. Therefore, FABPs represent potential novel targets as cancer biomarkers and therapeutic targets. Future studies are needed to elucidate the mechanism of FABP3 and FABP4 in fatty acid metabolism and in NSCLC tumorigenesis.
Our study has several limitations. First, our study is a retrospective correlation study, thus we do not know whether FABP3 and FABP4 protein expression is the driving force of NSCLC progression or the consequence of NSCLC development. Larger prospective studies are needed to distinguish these two scenarios. Second, protein quantification by IHC analysis is subjective and semiquantitative; our results on FABP3 and FABP4 protein expression should be independently validated by other methods. Finally, we did not perform in vitro functional studies to elucidate the molecular mechanisms of FABP3 and FABP4 expression and NSCLC development.
In conclusion, our results demonstrated that both high FABP3 and FABP4 protein expression is associated with poor prognosis in NSCLC. Our study provides rationale to further investigate the involvement of fatty acid metabolism signaling pathway in NSCLC development as well as FABP3 and FABP4 as potential prognostic markers and therapeutic targets in NSCLC.
MATERIALS AND METHODS
Tissue samples
NSCLC cancerous tissues (n=281) and matched adjacent non-cancerous tissues (n=121) were collected as archived formalin fixed, paraffin embedded samples from human clinical biobank in Affiliated Hospital of Nantong University, Jiangsu Province, China. The ages of patients ranged from 35 to 83 years old, with a median of 62.1 years old, including 85 women and 196 men. All cases were histologically diagnosed with NSCLC. None of the patients had received neo-adjuvant chemotherapy, radiotherapy or immunotherapy before surgery. All patients had signed informed consent before surgery and the Research Ethics Committee approved this study.
Quantitative real-time reverse transcription PCR (qRT-PCR)
The Department of Pathology at the Affiliated Hospital of Nantong University provided the fresh frozen NSCLC cancerous tissues (n=30) and matched adjacent non-cancerous tissues (n=30). Total RNA was extracted from these samples using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and about 2 μg of total RNA was reverse transcribed into cDNA using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). The following oligonucleotide primers were used for PCR amplification: 
Tissue microarrays (TMA) construction and immunohistochemistry (IHC) analysis
NSCLC cancerous and matched adjacent noncancerous tissues were prepared for TMAs. The manual Tissue Microarray System Quick-Ray (UT06, UNITMA, Korea) was used to generate TMAs. Core tissue samples (diameter of 2 mm) were obtained from paraffin embedded tissue sections and deposited in paraffin-recipient blocks. Before immunohistochemical processing, the tissue microarray specimens were cut into 4-μm-thick sections and placed on the super frost charged glass microscope slides. IHC was carried out as described before [50] . Briefly, the slides were incubated with the primary antibodies for FABP3 (1:100; Abcam, Cambridge, MA, USA) and FABP4 (1:100; Abcam, Cambridge, MA, USA) overnight at 4°C. Subsequently, the slides were incubated with anti-mouse IgG secondary antibody (Abcam) for FABP3 and horseradish-peroxidase-conjugated rabbit IgG (Abcam) for FABP4. Diaminobenzidine solution was used for the color development.
TMA-IHC data evaluation
IHC staining was scored independently by two individuals, who were blinded to each other's findings and the clinical characteristics of these samples. Protein expression was analyzed by the staining intensity and the percentage of cells stained. The staining intensity was scored as 0 (no), 1 (weak), 2 (moderate), and 3 (strong), then multiplied by the percentage of positive cells. Therefore, the final score ranged from 0 (no cells with any staining) to 300 (all cells with strong staining). The protein expression was then dichotomized into low protein expression and high protein expression using a cutoff point determined by the X-file software (Rimm Laboratory at Yale University; http://www.tissuearray.org/rimmlab) as previously introduced [51] . In this study, the cutoff points for FABP3 and FABP4 were 90 and 120 respectively: expression score equal or higher than the cutoff point was considered high expression, while expression score lower than the cutoff point was considered low expression.
Statistical analysis
Pearson χ2 test was used to evaluate the correlation of FABP3 and FABP4 expression with clinicopathological characteristics of NSCLC patients. Spearman correlation test was performed to determine the correlation between FABP3 and FABP4 protein expression. Both univariate and multivariate Cox regression analysis were used to identify independent prognostic factors. KaplanMeier and the log-rank tests were used to calculate survival curves. P value of less than 0.05 was regarded as statistically significant. All statistical analyses were accomplished in SPSS version 20.0 statistical software (SPSS Inc., Chicago, IL, USA).
